Combination Therapy with Radiation

Genelux Corporation is actively studying the effects of integrating oncolytic virotherapy with standard radiation therapy after some interesting preclinical results showed promising synergy. Researchers evaluated the combination of focal ionizing radiation (IR) combined with systemically-delivered oncolytic vaccinia virus GL-ONC1 in mice bearing human glioma xenografts and found that irradiating glioma tumors PRIOR to administering GL-ONC1 resulted in a significant sensitization of these tumors to oncolytic virotherapy compared to those which were not previously irradiated prior to virotherapy. These findings are the basis for ongoing Genelux-sponsored human clincal trials involving a combination of vaccinia-based virotherapy, radiation therapy and chemotherapy.